Novavax to expand Maryland facility to support global vaccine development

pharmafile | November 3, 2020 | News story | Manufacturing and Production  

Novavax has announced that it plans to expand its Maryland campus to facilitate the company’s growth as it develops its coronavirus vaccine candidate.

The company is currently carrying out Phase 3 clinical trials in the UK and is set to begin another in the US and Mexico this month. Several Phase 2 trials are ongoing and others are in the planning phase at multiple sites. The company has received $2 billion in funding for its coronavirus vaccine, including $1.6 billion from the US Government and $388 million from the Coalition for Epidemic Preparedness Innovations (CEPI).

Novavax holds an existing 15-year lease with the Maryland site, and will look to expand on this beginning early 2021.

Stanley C Erck, President and CEO of Novavax, said: “The expansion of our physical footprint reflects Novavax’ significant growth as we work to both rapidly deliver a COVID-19 vaccine and progress NanoFlu, our influenza vaccine candidate, for regulatory submission and potential commercialisation.

“We appreciate the support, partnership and speed of the Maryland Department of Commerce, Montgomery County, and the City of Gaithersburg, which have enabled the expansion of our operations, enhanced our ability to retain and attract highly skilled employees, and reinforced our longstanding commitment to the biotechnology sector in Maryland.”

As well as coronavirus vaccines, the company is also testing influenza vaccine candidates. Earlier this year it reported positive Phase 3 data for NanoFlu.

Conor Kavanagh

Related Content

No items found

Latest content